Eli Lilly Stock Drops After Earnings. Its Guidance Disappoints.

📆 02/11/2023 13:31:00
📰 MarketWatch

⏱ Reading Time:
26 sec. here
2 min. at publisher
📊 Quality Score:
News: 14%
Publisher: 97%

Portugal Notícia Notícia

Portugal Últimas Notícias,Portugal Manchetes

The drugmaker slashes its guidance for full-year earnings to a range of $6.50 to $6.70 a share, having raised its outlook in August to a range of $9.70 to...

Eli Lilly stock slipped on Thursday after the drugmaker significantly slashed its full-year earnings guidance on the back of a deal spree.

What disappointed was the outlook. Lilly slashed its guidance for full-year earnings to a range of $6.50 to $6.70 a share, having raised its outlook in August to a range of $9.70 to $9.90. “Lilly had another strong quarter in Q3 as Mounjaro and Verzenio continued to gain momentum,” David A. Ricks, the group’s chairman and CEO, said in a statement. “Lilly executed on business development priorities in the third quarter including multiple acquisitions that expand our already robust pipeline.”

Resumimos esta notícia para que você possa lê-la rapidamente. Se você se interessou pela notícia, pode ler o texto completo aqui. Consulte Mais informação:

Escrever Comentário

Portugal Últimas Notícias, Portugal Manchetes

Similar News:Você também pode ler notícias semelhantes a esta que coletamos de outras fontes de notícias.

Eli Lilly Stock Slumps as Earnings Guidance Slashed DramaticallyLilly slashes its guidance for full-year earnings to a range of $6.50 to $6.70 a share, having raised its outlook in August to a range of $9.70 to $9.90.
Fonte: MarketWatch - 🏆 3. / 97 Consulte Mais informação »